Thrombolysis for acute ischaemic stroke
Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory J del Zoppo, Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory J del Zoppo
Abstract
Background: Most strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred and improve recovery after stroke in some people. Thrombolytic drugs, however, can also cause serious bleeding in the brain, which can be fatal. One drug, recombinant tissue plasminogen activator (rt-PA), is licensed for use in selected patients within 4.5 hours of stroke in Europe and within three hours in the USA. There is an upper age limit of 80 years in some countries, and a limitation to mainly non-severe stroke in others. Forty per cent more data are available since this review was last updated in 2009.
Objectives: To determine whether, and in what circumstances, thrombolytic therapy might be an effective and safe treatment for acute ischaemic stroke.
Search methods: We searched the Cochrane Stroke Group Trials Register (last searched November 2013), MEDLINE (1966 to November 2013) and EMBASE (1980 to November 2013). We also handsearched conference proceedings and journals, searched reference lists and contacted pharmaceutical companies and trialists.
Selection criteria: Randomised trials of any thrombolytic agent compared with control in people with definite ischaemic stroke.
Data collection and analysis: Two review authors applied the inclusion criteria, extracted data and assessed trial quality. We verified the extracted data with investigators of all major trials, obtaining additional unpublished data if available.
Main results: We included 27 trials, involving 10,187 participants, testing urokinase, streptokinase, rt-PA, recombinant pro-urokinase or desmoteplase. Four trials used intra-arterial administration, while the rest used the intravenous route. Most data come from trials that started treatment up to six hours after stroke. About 44% of the trials (about 70% of the participants) were testing intravenous rt-PA. In earlier studies very few of the participants (0.5%) were aged over 80 years; in this update, 16% of participants are over 80 years of age due to the inclusion of IST-3 (53% of participants in this trial were aged over 80 years). Trials published more recently utilised computerised randomisation, so there are less likely to be baseline imbalances than in previous versions of the review. More than 50% of trials fulfilled criteria for high-grade concealment; there were few losses to follow-up for the main outcomes.Thrombolytic therapy, mostly administered up to six hours after ischaemic stroke, significantly reduced the proportion of participants who were dead or dependent (modified Rankin 3 to 6) at three to six months after stroke (odds ratio (OR) 0.85, 95% confidence interval (CI) 0.78 to 0.93). Thrombolytic therapy increased the risk of symptomatic intracranial haemorrhage (OR 3.75, 95% CI 3.11 to 4.51), early death (OR 1.69, 95% CI 1.44 to 1.98; 13 trials, 7458 participants) and death by three to six months after stroke (OR 1.18, 95% CI 1.06 to 1.30). Early death after thrombolysis was mostly attributable to intracranial haemorrhage. Treatment within three hours of stroke was more effective in reducing death or dependency (OR 0.66, 95% CI 0.56 to 0.79) without any increase in death (OR 0.99, 95% CI 0.82 to 1.21; 11 trials, 2187 participants). There was heterogeneity between the trials. Contemporaneous antithrombotic drugs increased the risk of death. Trials testing rt-PA showed a significant reduction in death or dependency with treatment up to six hours (OR 0.84, 95% CI 0.77 to 0.93, P = 0.0006; 8 trials, 6729 participants) with significant heterogeneity; treatment within three hours was more beneficial (OR 0.65, 95% CI 0.54 to 0.80, P < 0.0001; 6 trials, 1779 participants) without heterogeneity. Participants aged over 80 years benefited equally to those aged under 80 years, particularly if treated within three hours of stroke.
Authors' conclusions: Thrombolytic therapy given up to six hours after stroke reduces the proportion of dead or dependent people. Those treated within the first three hours derive substantially more benefit than with later treatment. This overall benefit was apparent despite an increase in symptomatic intracranial haemorrhage, deaths at seven to 10 days, and deaths at final follow-up (except for trials testing rt-PA, which had no effect on death at final follow-up). Further trials are needed to identify the latest time window, whether people with mild stroke benefit from thrombolysis, to find ways of reducing symptomatic intracranial haemorrhage and deaths, and to identify the environment in which thrombolysis may best be given in routine practice.
Conflict of interest statement
The Division of Clinical Neurosciences at the University of Edinburgh had a collaborative project with Boehringer Ingelheim (UK) to establish a research magnetic resonance scanner, through the UK Research Councils Joint Research Equipment Initiative in 1997. For this, the Division received a grant from Boehringer Ingelheim, manufacturers of rt‐PA in Europe, towards the purchase of the scanner. Further details of competing interests are listed on the Division's web site (www.dcn.ed.ac.uk).
The Division of Clinical Neurosciences at the University of Edinburgh are co‐ordinating the Third International Stroke Trial (IST3 2012) of intravenous tissue Plasminogen Activator within six hours of acute ischaemic stroke. Prof Joanna Wardlaw is the Imaging Principal Investigator of this trial, Dr Veronica Murray is the Swedish National Co‐ordinator and Dr Eivind Berge is the Norwegian National Co‐ordinator for IST‐3. The start‐up phase was funded by the UK Stroke Association and PPP Foundation, with a limited supply of drug and placebo for the first part of the start‐up phase from Boehringer Ingelheim; the main trial is funded by the UK Medical Research Council.
Prof Joanna Wardlaw received payment from Boehringer Ingelheim for reading scans for ECASS 3 on a cost‐per‐scan basis up to 2008. She was/is on the Steering Committees of MAST‐I 1995, IST3 2012, and contributed to the design of ECASS 3 2008 (first Steering Committee meeting and design of scan reading). Boehringer Ingelheim applied for an extension to the licence for rt‐PA from three to 4.5 hours on the basis of the ECASS 3 2008 result and supporting data, such as individual patient data analyses and the Cochrane review.
The review was assembled, analysed and reported independent of any sponsor or pharmaceutical company.
Figures
![1.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-01.jpg)
![1.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-02.jpg)
![1.3. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-03.jpg)
![1.4. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-04.jpg)
![1.5. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-05.jpg)
![1.6. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-06.jpg)
![1.7. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-07.jpg)
![1.8. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-08.jpg)
![1.9. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-09.jpg)
![1.10. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-10.jpg)
![1.11. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-11.jpg)
![1.12. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-12.jpg)
![1.13. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-13.jpg)
![1.14. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-14.jpg)
![1.15. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-15.jpg)
![1.16. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-16.jpg)
![1.17. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-17.jpg)
![1.18. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-18.jpg)
![1.19. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-19.jpg)
![1.20. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-20.jpg)
![1.21. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-21.jpg)
1.22. Analysis
Comparison 1 Any thrombolytic agent…
1.22. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 22 Alive and favourable outcome…
1.23. Analysis
Comparison 1 Any thrombolytic agent…
1.23. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 23 Deaths from all causes…
1.24. Analysis
Comparison 1 Any thrombolytic agent…
1.24. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 24 Deaths by time to…
1.25. Analysis
Comparison 1 Any thrombolytic agent…
1.25. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 25 Deaths by time to…
1.26. Analysis
Comparison 1 Any thrombolytic agent…
1.26. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 26 Deaths by time to…
1.27. Analysis
Comparison 1 Any thrombolytic agent…
1.27. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 27 Death by latest time…
1.28. Analysis
Comparison 1 Any thrombolytic agent…
1.28. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 28 Symptomatic intracranial haemorrhage by…
1.29. Analysis
Comparison 1 Any thrombolytic agent…
1.29. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 29 Symptomatic intracranial haemorrhage by…
1.30. Analysis
Comparison 1 Any thrombolytic agent…
1.30. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 30 Symptomatic intracranial haemorrhage by…
1.31. Analysis
Comparison 1 Any thrombolytic agent…
1.31. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 31 Death or dependency (mRS…
1.32. Analysis
Comparison 1 Any thrombolytic agent…
1.32. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 32 Death or dependency (mRS…
1.33. Analysis
Comparison 1 Any thrombolytic agent…
1.33. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 33 Alive and independent (mRS…
1.34. Analysis
Comparison 1 Any thrombolytic agent…
1.34. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 34 Alive and independent (mRS…
1.35. Analysis
Comparison 1 Any thrombolytic agent…
1.35. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 35 Alive and independent (mRS…
1.36. Analysis
Comparison 1 Any thrombolytic agent…
1.36. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 36 Death: selection by MR…
1.37. Analysis
Comparison 1 Any thrombolytic agent…
1.37. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 37 Death or dependency: selection…
1.38. Analysis
Comparison 1 Any thrombolytic agent…
1.38. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 38 Symptomatic intracranial haemorrhage: selection…
1.39. Analysis
Comparison 1 Any thrombolytic agent…
1.39. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 39 Alive and independent (mRS…
1.40. Analysis
Comparison 1 Any thrombolytic agent…
1.40. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 40 Death or dependency at…
- Thrombolysis for acute ischaemic stroke.Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Wardlaw JM, et al. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD000213. doi: 10.1002/14651858.CD000213.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821269 Updated. Review.
- Thrombolysis for acute ischaemic stroke.Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Wardlaw JM, et al. Cochrane Database Syst Rev. 2003;(3):CD000213. doi: 10.1002/14651858.CD000213. Cochrane Database Syst Rev. 2003. PMID: 12917889 Updated. Review.
- Thrombolysis for acute ischaemic stroke.Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Wardlaw JM, et al. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD000213. doi: 10.1002/14651858.CD000213.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821269 Updated. Review.
- Thrombolysis for acute ischaemic stroke.Wardlaw JM, del Zoppo G, Yamaguchi T. Wardlaw JM, et al. Cochrane Database Syst Rev. 2000;(2):CD000213. doi: 10.1002/14651858.CD000213. Cochrane Database Syst Rev. 2000. PMID: 10796329 Updated. Review.
- Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke.Wardlaw JM, Koumellis P, Liu M. Wardlaw JM, et al. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD000514. doi: 10.1002/14651858.CD000514.pub3. Cochrane Database Syst Rev. 2013. PMID: 23728633 Free PMC article. Review.
- Percutaneous vascular interventions for acute ischaemic stroke.O'Rourke K, Berge E, Walsh CD, Kelly PJ. O'Rourke K, et al. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD007574. doi: 10.1002/14651858.CD007574.pub2. Cochrane Database Syst Rev. 2010. PMID: 20927761 Updated. Review.
- Factors Determining Not Returning to Full-Time Work 12 Months After Mild Ischemic Stroke.Vlachos G, Ihle-Hansen H, Wyller TB, Brækhus A, Mangset M, Hamre C, Fure B. Vlachos G, et al. Arch Rehabil Res Clin Transl. 2022 Nov 12;5(1):100245. doi: 10.1016/j.arrct.2022.100245. eCollection 2023 Mar. Arch Rehabil Res Clin Transl. 2022. PMID: 36968174 Free PMC article.
- What is the current provision of service for gastrostomy insertion in England?Parr H, Williams EA, White S, Thompson N, McAlindon ME, Hopper AD, McKinlay A, Sanders DS. Parr H, et al. Frontline Gastroenterol. 2022 Oct 6;14(2):138-143. doi: 10.1136/flgastro-2022-102154. eCollection 2023. Frontline Gastroenterol. 2022. PMID: 36818792
- Predictors and long-term outcome of intracranial hemorrhage after thrombolytic therapy for acute ischemic stroke-A prospective single-center study.Fekete KE, Héja M, Márton S, Tóth J, Harman A, Horváth L, Fekete I. Fekete KE, et al. Front Neurol. 2023 Feb 1;14:1080046. doi: 10.3389/fneur.2023.1080046. eCollection 2023. Front Neurol. 2023. PMID: 36816554 Free PMC article.
- Correlation Between Pre-treatment Collateral Status and Short-Term Functional Outcome in Patients With Mild to Moderate Stroke After Reperfusion Therapy in a Local Primary Stroke Center in the Southwestern Part of Saudi Arabia.Alqahtani SA, Alnaami I, Alhazzani A, Alahmari F, Wassel Y, Elsayed E, Abdrabou A, Bassiouny Mohamed AA. Alqahtani SA, et al. Cureus. 2023 Jan 20;15(1):e33997. doi: 10.7759/cureus.33997. eCollection 2023 Jan. Cureus. 2023. PMID: 36811050 Free PMC article.
- Clinical experience: Outcomes of mesenchymal stem cell transplantation in five stroke patients.Ercelen N, Karasu N, Kahyaoglu B, Cerezci O, Akduman RC, Ercelen D, Erturk G, Gulay G, Alpaydin N, Boyraz G, Monteleone B, Kural Z, Silek H, Temur S, Bingol CA. Ercelen N, et al. Front Med (Lausanne). 2023 Jan 19;10:1051831. doi: 10.3389/fmed.2023.1051831. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36744151 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Brain Ischemia / drug therapy
- Drug Administration Schedule
- Fibrinolytic Agents / adverse effects
- Fibrinolytic Agents / therapeutic use*
- Humans
- Intracranial Hemorrhages / chemically induced
- Randomized Controlled Trials as Topic
- Stroke / drug therapy*
- Stroke / etiology
- Stroke / mortality
- Thrombolytic Therapy* / adverse effects
- Time-to-Treatment
- Tissue Plasminogen Activator / adverse effects
- Tissue Plasminogen Activator / therapeutic use
- Fibrinolytic Agents
- Tissue Plasminogen Activator
- Full Text Sources
- Other Literature Sources
- Medical
![1.22. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-22.jpg)
1.23. Analysis
Comparison 1 Any thrombolytic agent…
1.23. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 23 Deaths from all causes…
1.24. Analysis
Comparison 1 Any thrombolytic agent…
1.24. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 24 Deaths by time to…
1.25. Analysis
Comparison 1 Any thrombolytic agent…
1.25. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 25 Deaths by time to…
1.26. Analysis
Comparison 1 Any thrombolytic agent…
1.26. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 26 Deaths by time to…
1.27. Analysis
Comparison 1 Any thrombolytic agent…
1.27. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 27 Death by latest time…
1.28. Analysis
Comparison 1 Any thrombolytic agent…
1.28. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 28 Symptomatic intracranial haemorrhage by…
1.29. Analysis
Comparison 1 Any thrombolytic agent…
1.29. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 29 Symptomatic intracranial haemorrhage by…
1.30. Analysis
Comparison 1 Any thrombolytic agent…
1.30. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 30 Symptomatic intracranial haemorrhage by…
1.31. Analysis
Comparison 1 Any thrombolytic agent…
1.31. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 31 Death or dependency (mRS…
1.32. Analysis
Comparison 1 Any thrombolytic agent…
1.32. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 32 Death or dependency (mRS…
1.33. Analysis
Comparison 1 Any thrombolytic agent…
1.33. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 33 Alive and independent (mRS…
1.34. Analysis
Comparison 1 Any thrombolytic agent…
1.34. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 34 Alive and independent (mRS…
1.35. Analysis
Comparison 1 Any thrombolytic agent…
1.35. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 35 Alive and independent (mRS…
1.36. Analysis
Comparison 1 Any thrombolytic agent…
1.36. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 36 Death: selection by MR…
1.37. Analysis
Comparison 1 Any thrombolytic agent…
1.37. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 37 Death or dependency: selection…
1.38. Analysis
Comparison 1 Any thrombolytic agent…
1.38. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 38 Symptomatic intracranial haemorrhage: selection…
1.39. Analysis
Comparison 1 Any thrombolytic agent…
1.39. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 39 Alive and independent (mRS…
1.40. Analysis
Comparison 1 Any thrombolytic agent…
1.40. Analysis
Comparison 1 Any thrombolytic agent versus control, Outcome 40 Death or dependency at…
![1.23. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-23.jpg)
![1.24. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-24.jpg)
![1.25. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-25.jpg)
![1.26. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-26.jpg)
![1.27. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-27.jpg)
![1.28. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-28.jpg)
![1.29. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-29.jpg)
![1.30. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-30.jpg)
![1.31. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-31.jpg)
![1.32. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-32.jpg)
![1.33. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-33.jpg)
![1.34. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-34.jpg)
![1.35. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-35.jpg)
![1.36. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-36.jpg)
![1.37. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-37.jpg)
![1.38. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-38.jpg)
![1.39. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-39.jpg)
![1.40. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7032668/bin/nCD000213-CMP-001-40.jpg)
Source: PubMed